Stellar Biotechnologies Announces Publication of “Expert Review” Article on Clostridium difficile Vaccines
PORT HUENEME, CA, (April 30, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced publication of a peer-reviewed article on Clostridium difficile (“C. difficile”) in the current issue of Expert Review of Vaccines (April 2013, Vol. 12, No.4.).
C. difficile is a potentially fatal intestinal superbug that is fast emerging as the most common hospital-based infection in the United States. Rates of C. difficile infection are at historic highs due to its resistance to common treatments.
The paper titled “Carbohydrate-based Clostridium difficile Vaccines” was co-authored by scientists from Stellar, the University of Arizona and the University of Guelph (Ontario, Canada). In 2012, Stellar entered into an agreement with the University of Guelph for the exclusive option to license technology for the development of a vaccine candidate against C. difficile. The Company is currently evaluating KLH-conjugate vaccine candidates in preclinical studies.
The article describes biochemical characteristics of C. difficile that support the University of Guelph’s carbohydrate-based vaccine approach to potential C. difficile treatment. The strategy utilizes Stellar KLH as a carrier/adjuvant for C. difficile PSII polysaccharide and the article recapped the team’s preclinical work demonstrating PSII/KLH conjugation, vaccine immunogenicity, and KLH as an adjuvant to stimulate intestinal immunity.
Vaccines composed of C. difficile polysaccharides and KLH represent promising next-generation treatments for this formidable disease.